Denali Therapeutics Inc.
DNLI
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.5B
$22.28
▼ -2.28%
P/E
-7.85
Mkt Cap
$3.5B
52-Wk Range
$12.58–$27.30
52-Week Range
$12.58 - $27.30
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 43.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Strategic partnerships with pharmaceutical giants (Takeda, Genentech, Sanofi) providing capital and expertise
- Proprietary LRRK2 inhibitor platform with clinical validation in Parkinson's disease
- Diversified pipeline targeting multiple neurodegenerative indications reducing development risk
- Collaboration with leading research institutions and patient advocacy organizations (Michael J. Fox Foundation)
- Antisense therapy research agreement with Secarna Pharmaceuticals expanding therapeutic modalities
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Growing mid-cap in Biotechnology
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+14.0% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DNLI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.68 vs -$0.51 consensus (-32.5% surprise). Revenue of $3.6M vs $2.2M expected (+67.3%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-32.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$3.6M
Margins · last 8Q
Gross
0.0%
Profit
-3539.2%
Wall Street consensus
12 analysts · 92% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
92%
Hold
8%
Sell
0%
Median Price Target
—
Latest: B. Riley · Aug 25, 2026
vs Industry
How DNLI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related